Roche says Alzheimer’s trials failed in disappointment for field
When Biogen and Eisai succeeded in trials with a potential treatment for the dementia disease, Roche warned that not all Alzheimer’s candidates would make the same leap – now, its own candidate has failed.
By Naomi Kresge, bloomberg
Roche Holding AG has revealed that a long-awaited experimental drug for Alzheimer’s disease has failed in a pair of large studies, another disappointment in a research field marred with failures.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
